CONNECT WITH US:
Sep 06, 2022 14:00 JST
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs
SYDNEY, AU, Sep 06, 2022 - (ACN Newswire) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program.
Watch the video here:
Avance Clinical is the largest and most established full-service Australian and New Zealand CRO with a proven track-record of data acceptance by the FDA and all other major regulatory bodies.
The combined Avance Clinical Australia, New Zealand, and North American operations deliver a unique GlobalReady drug development model for biotechs.
Avance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical has been working with C3 Research Associates in recent years and they share a similar culture and focus on customer service and clinical excellence. This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical's expansion plans into North America. The due diligence process has taken more than 6 months and we are excited to now welcome our US team and offer the GlobalReady model for our clients.
"This acquisition gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. This GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA accepted data.
"In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximise their rebate potential.
"We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities.
"We will be making significant investments in our US operations including growing the team to more than 120 people and leveraging their deep industry experience across a broad range of therapeutic areas, in particular oncology.
Clients can be assured the world-class best practice technologies, systems and processes will be integrated across all regions."
This seamless GlobalReady journey is designed for success whereby biotechs can:
- Take advantage of the Australian early phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalise global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.
The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.
Avance Clinical's has achieved high growth and industry-leading repeat business rates with its focus on gold standard technology paired with solution-orientated clinical experts. This is the mix that biopharma clients clearly require in this fast-moving, competitive and high-stakes sector.
Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.
Learn about the Australian Advantage here:
Meet the North American leadership team here:
For more information about the benefits of running your next study with Avance Clinical contact us
About Avance Clinical
Avance Clinical is the largest premium full-service Australian CRO with operations across Australia, New Zealand and North America delivering quality clinical trials with globally accepted data for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.
Pre-clinical to Later Phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to later phase clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM and Medrio are just some of the technology partners.
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Delica Mini Wins 2023-2024 Japan Car of the Year Design Award
Dec 08, 2023 21:07 JST
Space Compass, NTT DOCOMO, NTT and SKY Perfect JSAT to Develop Direct-to-Device Service via Space-based Non-terrestrial Network
Dec 08, 2023 17:34 JST
MHI and ADNOC Sign Agreement to Explore Low Carbon Collaboration Opportunities to Build Blue NH3 and Blue H2 Value Chains
Dec 08, 2023 17:22 JST
MHI and Mitsubishi Logisnext Receive First Order from Kirin Group for an Automated Picking Solution
Dec 08, 2023 17:09 JST
Macau LRT Barra Extension Line Begins Commercial Operations on December 8
Dec 08, 2023 17:07 JST
Fujitsu and Palantir to strengthen strategic partnership to solve societal challenges and accelerate business transformation globally
Dec 08, 2023 16:28 JST
Honda to Begin Sales of Refreshed Odyssey in Japan
Dec 07, 2023 16:30 JST
Honda to Premiere New EV Series for Global Markets at CES 2024
Dec 07, 2023 13:00 JST
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
Dec 07, 2023 11:00 JST
Hitachi High-Tech Launches Dark Field Wafer Defect Inspection System DI4600 to Provide High Throughput and High-Precision Defect Detection on Patterned Wafers
Dec 06, 2023 17:38 JST
Fujitsu optimizes installation of EV charging infrastructure in India with Fujitsu Fleet Optimization solution trial
Dec 06, 2023 11:02 JST
Fujitsu Finland to provide comprehensive IT services to Kempower, provider of electric vehicle fast charging solutions
Dec 05, 2023 10:52 JST
DENSO Announces Organizational and Executive Changes
Dec 04, 2023 18:12 JST
All-New Triton Earns Top Rating in 2023 ASEAN NCAP
Dec 04, 2023 17:07 JST
Fujitsu and KDDI Research successfully implement large-capacity multiband wavelength multiplexing transmission with installed optical fiber
Dec 04, 2023 10:34 JST
GC Collaborates with MHI to explore the utilization of hydrogen, ammonia and CCS technology to develop a large-scale petrochemical plant to achieve Net Zero
Dec 01, 2023 17:22 JST
NEC named among IAM's 2023 Asia IP Elite
Dec 01, 2023 14:50 JST
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 16:25 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised
Nov 30, 2023 16:17 JST
Olympus's Net-Zero Targets Approved by SBTi
Nov 30, 2023 11:00 JST
More Latest Release >>
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
April 18 2023 11:00 JST
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
January 11 2023 15:00 JST
Avance Clinical Wins International Health Award for Biotech CRO Services
September 28 2022 16:00 JST
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022
August 29 2022 18:00 JST
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
April 19 2022 10:00 JST
Avance Clinical Announces New Office Opening in Melbourne
March 31 2022 15:00 JST
Avance Clinical Announces New Office Opening in Sydney
March 02 2022 15:00 JST
More Press release >>